Promote Sponsor
verified SJR 0,428 · Q3 • database DOAJ indexed
Malaria Research and Treatment
Egypt · Hindawi Limited
workspace_premium Q3 — Infectious Diseases verified Plan S Compliant visibility_off Single blind Peer Review lock_open Open Access · DOAJ Unclaimed

Malaria Research and Treatment

Malaria Research and Treatment is a journal indexed in SJR in Infectious Diseases and Epidemiology with an H index of 20. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 697.5 €. The scope of the journal is focused on malaria, plasmodium, antimalarials. It has an SJR impact factor of 0,428 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,428.

ISSN: 2090-8075
Editorial: Hindawi Limited
Category: Infectious Diseases
Indexation: verifiedDOAJ

Unclaimed profile — some fields may be incomplete.

open_in_new Portal NPD menu_book Guía para Autores (Guidelines)
schedule Datos CoP · solo campos en BD
SJR Impact Factor trending_up
0,428 Q3
H-index 20
Tasa de Aceptación pie_chart
42%
Fuente Acceptance_Rate
Tiempo a publicación hourglass_top
15 semanas
Campo Average_time_publication_weeks
Coste de Publicación (APC) payments
698 € Open Access
Ruta Non-OA NPD

Metrics

Campos Scimago / CoP — sin series inventadas

DOAJ

SJR Impact

0,428

H-index

20

Docs (year)

0

Docs 3y

11

Total refs

0

Cites 3y

26

Citable 3y

11

Cites/Doc 2y

0

Ref/Doc

0.0

Immediate OA

697.5 €

Embargoed OA

NPD

Non OA / Submission

- €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

FAQS